Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.

× No keyword cloud information.

5 in total

1. The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.

Authors: Anna Vidal-Crespo; Vanina Rodriguez; Alba Matas-Cespedes; Eriong Lee; Alfredo Rivas-Delgado; Eva Giné; Alba Navarro; Sílvia Beà; Elias Campo; Armando López-Guillermo; Monica Lopez-Guerra; Gaël Roué; Dolors Colomer; Patricia Pérez-Galán
Journal: Haematologica Date: 2017-08-24 Impact factor: 9.941

2. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.

Authors: Chiara Tarantelli; Eugenio Gaudio; Alberto J Arribas; Ivo Kwee; Petra Hillmann; Andrea Rinaldi; Luciano Cascione; Filippo Spriano; Elena Bernasconi; Francesca Guidetti; Laura Carrassa; Roberta Bordone Pittau; Florent Beaufils; Reto Ritschard; Denise Rageot; Alexander Sele; Barbara Dossena; Francesca Maria Rossi; Antonella Zucchetto; Monica Taborelli; Valter Gattei; Davide Rossi; Anastasios Stathis; Georg Stussi; Massimo Broggini; Matthias P Wymann; Andreas Wicki; Emanuele Zucca; Vladimir Cmiljanovic; Doriano Fabbro; Francesco Bertoni
Journal: Clin Cancer Res Date: 2017-10-24 Impact factor: 12.531

3. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Authors: John C Byrd; Bonnie Harrington; Susan O'Brien; Jeffrey A Jones; Anna Schuh; Steve Devereux; Jorge Chaves; William G Wierda; Farrukh T Awan; Jennifer R Brown; Peter Hillmen; Deborah M Stephens; Paolo Ghia; Jacqueline C Barrientos; John M Pagel; Jennifer Woyach; Dave Johnson; Jane Huang; Xiaolin Wang; Allard Kaptein; Brian J Lannutti; Todd Covey; Maria Fardis; Jesse McGreivy; Ahmed Hamdy; Wayne Rothbaum; Raquel Izumi; Thomas G Diacovo; Amy J Johnson; Richard R Furman
Journal: N Engl J Med Date: 2015-12-07 Impact factor: 91.245

4. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.

Authors: Michael Wang; Simon Rule; Pier Luigi Zinzani; Andre Goy; Olivier Casasnovas; Stephen D Smith; Gandhi Damaj; Jeanette Doorduijn; Thierry Lamy; Franck Morschhauser; Carlos Panizo; Bijal Shah; Andrew Davies; Richard Eek; Jehan Dupuis; Eric Jacobsen; Arnon P Kater; Steven Le Gouill; Lucie Oberic; Taduesz Robak; Todd Covey; Richa Dua; Ahmed Hamdy; Xin Huang; Raquel Izumi; Priti Patel; Wayne Rothbaum; J Greg Slatter; Wojciech Jurczak
Journal: Lancet Date: 2017-12-11 Impact factor: 79.321

Review 5. Role of Bruton's tyrosine kinase in B cells and malignancies.

Authors: Simar Pal Singh; Floris Dammeijer; Rudi W Hendriks
Journal: Mol Cancer Date: 2018-02-19 Impact factor: 27.401

5 in total

4 in total

Review 1. Zanubrutinib: First Approval.

Authors: Yahiya Y Syed
Journal: Drugs Date: 2020-01 Impact factor: 9.546

Review 2. Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019.

Authors: Xuetong Chu; Yizhi Bu; Xiaoping Yang
Journal: Front Oncol Date: 2021-12-17 Impact factor: 6.244

3. Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series.

Authors: Yan Zhang; Yanan Li; Zhe Zhuang; Wei Wang; Chong Wei; Danqing Zhao; Daobin Zhou; Wei Zhang
Journal: Front Oncol Date: 2021-12-24 Impact factor: 6.244

Review 4. Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.

Authors: Núria Profitós-Pelejà; Juliana Carvalho Santos; Ana Marín-Niebla; Gaël Roué; Marcelo Lima Ribeiro
Journal: Cancers (Basel) Date: 2022-02-09 Impact factor: 6.639

4 in total